array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Novartis Gene Therapies, Inc." ["slug"]=> string(19) "a26d9-us-avexis-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/35cea00f-69c0-468d-b166-ddd4f49dfa0c" ["description"]=> string(639) "Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. Around 108,000 people of more than 140 nationalities work at Novartis around the world. See our community guidelines: http://bit.ly/2JnT2CP" ["address_street"]=> string(24) "2275 Half Day Rd Ste 200" ["address_place"]=> string(11) "Bannockburn" ["address_region"]=> string(8) "Illinois" ["founding_date"]=> string(10) "2010-02-28" ["website_domain"]=> string(12) "novartis.com" ["website_url"]=> string(24) "https://www.novartis.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(219) ["article_count"]=> int(7829) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(105) "European justice faced with the vagueness of the application of directives on funds in transition regimes" ["snippet_en"]=> string(235) "The Advocate General of the European Court of Justice has just delivered his conclusions in a case relating to the effective date of the full application of the provisions of the European directive on AIFM alternative investment funds." ["url"]=> string(159) "https://www.agefi.fr/asset-management/actualites/la-justice-europeenne-face-au-flou-de-lapplication-des-directives-sur-les-fonds-dans-les-regimes-de-transition" ["image_url"]=> string(78) "https://images.businessradar.com/articles/7b3cad6d-eec4-428c-87e9-08c437c4c071" ["source"]=> string(8) "agefi.fr" ["publication_date"]=> string(10) "2024-02-20" ["categories"]=> array(3) { [0]=> string(22) "EU Political Evolution" [1]=> string(5) "Legal" [2]=> string(8) "Verdicts" } } [1]=> array(7) { ["title_en"]=> string(102) "New "slap" on Frouzi from the Justice-He was sentenced for the bags with the 1 million | Pandora's box" ["snippet_en"]=> string(179) "The once powerful man of Novartis, Konstantinos Frouzis, was sentenced to 11 months in prison for the case of the bags of cash he delivered to a well-known restaurant in Kolonaki." ["url"]=> string(130) "https://www.koutipandoras.gr/article/neo-chastouki-se-frouzi-apo-tin-dikaiosyni-katadikastike-gia-tous-sakous-me-to-1-ekatommyrio/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/853ec7af-413d-487c-ba98-204f3044b962" ["source"]=> string(16) "koutipandoras.gr" ["publication_date"]=> string(10) "2024-01-07" ["categories"]=> array(2) { [0]=> string(5) "Legal" [1]=> string(8) "Verdicts" } } [2]=> array(7) { ["title_en"]=> string(80) "Daiichi Sankyo scores $182M from Novartis settlement in long-running patent case" ["snippet_en"]=> string(290) "After years of back and forth with Daiichi Sankyo over cancer drug patent claims, Novartis has thrown in the towel with a $182 million settlement. | In 2017, Daiichi's former subsidiary Plexxikon alleged that Novartis stepped on its Zelboraf patents with its GSK-acquired medicine Tafinlar." ["url"]=> string(114) "https://www.fiercepharma.com/pharma/novartis-forks-over-182m-settle-patent-claims-long-running-daiichi-sankyo-case" ["image_url"]=> string(78) "https://images.businessradar.com/articles/f7e7fe47-5f7b-45d2-889f-287208078289" ["source"]=> string(16) "fiercepharma.com" ["publication_date"]=> string(10) "2023-12-06" ["categories"]=> array(8) { [0]=> string(15) "Business Ethics" [1]=> string(5) "Legal" [2]=> string(16) "Case Settlements" [3]=> string(21) "Intellectual Property" [4]=> string(20) "Conflict of Interest" [5]=> string(27) "Business Model & Innovation" [6]=> string(46) "Management of Legal and Regulatory Environment" [7]=> string(8) "Verdicts" } } [3]=> array(7) { ["title_en"]=> string(60) "¬¬Study Spotlights Features of Infantile Hemangioma Subset" ["snippet_en"]=> string(105) "Detailed reports on this patient population are sparse and limited to case reports and small case series." ["url"]=> string(43) "https://www.medscape.com/viewarticle/997933" ["image_url"]=> string(78) "https://images.businessradar.com/articles/d4e1d24f-fe03-4955-96c9-d7f1121f02bc" ["source"]=> string(12) "medscape.com" ["publication_date"]=> string(10) "2023-10-31" ["categories"]=> array(3) { [0]=> string(5) "Legal" [1]=> string(8) "Verdicts" [2]=> string(16) "Case Settlements" } } [4]=> array(7) { ["title_en"]=> string(30) "Case: Patents/Stay (N.D. Cal.)" ["snippet_en"]=> string(288) "The court granted Novartis Pharmaceuticals Corporation’s motion to stay the Regents of the University of Michigan and the University of South Florida Board of Trustees’ action for infringement of a patent for blowable floccule insulation, pending inter partes review. Regents of Univ." ["url"]=> string(64) "https://news.bloomberglaw.com/ip-law/case-patents-stay-n-d-cal-8" ["image_url"]=> string(78) "https://images.businessradar.com/articles/6e019698-f0c1-4c97-a94e-0b8c7a988f3b" ["source"]=> string(16) "bloomberglaw.com" ["publication_date"]=> string(10) "2023-10-13" ["categories"]=> array(5) { [0]=> string(5) "Legal" [1]=> string(21) "Intellectual Property" [2]=> string(8) "Verdicts" [3]=> string(10) "Litigation" [4]=> string(17) "Academic Research" } } [5]=> array(7) { ["title_en"]=> string(100) "District Court Decision Teaches Caution When Construing Claims to Encompass After-Arising Technology" ["snippet_en"]=> string(296) "Novartis is currently involved in a multi-district patent litigation campaign to block generic entrants for its blockbuster heart medication. On July 7, the district court invalidated the patent for lack of written description despite rejecting an enablement defense based upon the same evidence." ["url"]=> string(137) "https://ipwatchdog.com/2023/07/13/district-court-decision-teaches-caution-construing-claims-encompass-after-arising-technology/id=163459/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/fcff9500-c68d-4162-b48a-f71f91d1129b" ["source"]=> string(14) "ipwatchdog.com" ["publication_date"]=> string(10) "2023-07-13" ["categories"]=> array(4) { [0]=> string(10) "Litigation" [1]=> string(5) "Legal" [2]=> string(46) "Management of Legal and Regulatory Environment" [3]=> string(8) "Verdicts" } } [6]=> array(7) { ["title_en"]=> string(93) "Novartis To Appeal To U.S. Court Of Appeals To Uphold Validity Of Entresto Combination Patent" ["snippet_en"]=> string(192) "BASEL (dpa-AFX) - Novartis (NVS) said the U.S. District Court for the District of Delaware ruled the Entresto (sacubitril / valsartan) 'combination patent' to be invalid. It will appeal to the" ["url"]=> string(162) "https://www.finanznachrichten.de/nachrichten-2023-07/59529752-novartis-to-appeal-to-u-s-court-of-appeals-to-uphold-validity-of-entresto-combination-patent-020.htm" ["image_url"]=> string(78) "https://images.businessradar.com/articles/e3aed23d-fe49-4a3e-97de-049ce0db52df" ["source"]=> string(20) "finanznachrichten.de" ["publication_date"]=> string(10) "2023-07-10" ["categories"]=> array(3) { [0]=> string(5) "Legal" [1]=> string(46) "Management of Legal and Regulatory Environment" [2]=> string(8) "Verdicts" } } [7]=> array(7) { ["title_en"]=> string(51) "Novartis plans appeal to ward off Entresto generics" ["snippet_en"]=> string(114) "Despite a loss at the district court level, Novartis is projecting a positive outlook for 2023 sales for Entresto." ["url"]=> string(99) "https://www.pharmaceutical-technology.com/news/novartis-plans-appeal-to-ward-off-entresto-generics/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/88819241-924c-4a75-b91c-9485eda1da08" ["source"]=> string(29) "pharmaceutical-technology.com" ["publication_date"]=> string(10) "2023-07-10" ["categories"]=> array(3) { [0]=> string(5) "Legal" [1]=> string(8) "Verdicts" [2]=> string(18) "General Investment" } } [8]=> array(7) { ["title_en"]=> string(45) "Novartis: negative court decision on Entresto" ["snippet_en"]=> string(150) "Novartis Announces that the US District Court in Delaware has ruled negatively regarding the validity of a patent covering Entresto - 07/10/2023 08:00" ["url"]=> string(91) "https://www.abcbourse.com/marches/novartis-decision-de-justice-negative-sur-entresto_599988" ["image_url"]=> NULL ["source"]=> string(13) "abcbourse.com" ["publication_date"]=> string(10) "2023-07-10" ["categories"]=> array(4) { [0]=> string(15) "Business Ethics" [1]=> string(5) "Legal" [2]=> string(46) "Management of Legal and Regulatory Environment" [3]=> string(8) "Verdicts" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(527) } [1]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(450) } [2]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(433) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(306) } [4]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(302) } [5]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(242) } [6]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(238) } [7]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(232) } [8]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(194) } [9]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(189) } [10]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(179) } [11]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(163) } [12]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(161) } [13]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(160) } [14]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(143) } [15]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(133) } [16]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(130) } [17]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(125) } [18]=> array(2) { ["name"]=> string(12) "Going Public" ["count"]=> int(119) } [19]=> array(2) { ["name"]=> string(8) "spin-off" ["count"]=> int(114) } [20]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(112) } [21]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(108) } [22]=> array(2) { ["name"]=> string(6) "Merger" ["count"]=> int(98) } [23]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(98) } [24]=> array(2) { ["name"]=> string(12) "Staff hiring" ["count"]=> int(85) } [25]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(85) } [26]=> array(2) { ["name"]=> string(7) "Layoffs" ["count"]=> int(81) } [27]=> array(2) { ["name"]=> string(15) "Business Ethics" ["count"]=> int(80) } [28]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(78) } [29]=> array(2) { ["name"]=> string(10) "Divestment" ["count"]=> int(74) } } } a26d9-us-avexis-inc